STAT+: Biotech’s rebound isn’t lifting all boats equally

Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Just in

STAT+: NIAID acting head John Powers III appointed as the permanent director

STAT+: Suing Joe the Plumber and Microsoft, and diminishing raises

Congo struggles to tame ebola outbreak six months into response
